Nama's AI scorecard currently rates ABIVAX Société Anonyme Sell (2.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ABVX report earnings?

ABIVAX Société Anonyme's next scheduled report is on Mar 22, 2027. Analysts expect EPS of -$0.89.

What is the ABVX price target?

The median analyst price target from 12 analysts is $164.00, with a range of $142.00 – $181.00.

Is ABVX Shariah compliant?

Nama's AAOIFI-style screen reads ABIVAX Société Anonyme as Can't Tell. A figure the screen needs is missing, so it can't tell.

Nama Insights

ABIVAX Société Anonyme (ABVX)

Healthcare · Biotechnology · NASDAQ

ABIVAX Société Anonyme (ABVX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.50B and a free-cash-flow yield of -3.0%. Nama's AI scorecard rates it Sell, 2.1 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 2.1/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Lagging · -16.3% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-42.4%

How far the last close sits under the highest price of the past five years.

Market cap	$7.50B
Trailing P/E	—
Price / book	16.7
Price / sales	1428.8
FCF yield	-3.0%
Dividend yield	—
Gross margin	100.0%
Operating margin	-8617.9%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	-0.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ABVX earnings

Next report: Mar 22, 2027 (Q4 2026, EPS estimate -$0.89). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Sep 21, 2026	-$1.69	-$0.86	-96.5%	$0
Q1 2026	May 22, 2026	-$0.71	-$0.81	+12.3%	$0
Q4 2025	Mar 23, 2026	-$1.18	-$1.04	-13.5%	$0
Q3 2025	Dec 15, 2025	-$2.47	-$0.79	-212.7%	$0

ABVX analyst price target

Median target $164.00 from 12 analysts, ranging $142.00 – $181.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ABVX data on Nama Insights →

ABVX FAQ

Is ABVX a buy?: Nama's AI scorecard currently rates ABIVAX Société Anonyme Sell (2.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ABVX report earnings?: ABIVAX Société Anonyme's next scheduled report is on Mar 22, 2027. Analysts expect EPS of -$0.89.
What is the ABVX price target?: The median analyst price target from 12 analysts is $164.00, with a range of $142.00 – $181.00.
Is ABVX Shariah compliant?: Nama's AAOIFI-style screen reads ABIVAX Société Anonyme as Can't Tell. A figure the screen needs is missing, so it can't tell.